Drug Misses Mark, but May Do Some Good in Diabetic Nephropathy

April 25, 2014 6:01 PM

16 0

Drug Misses Mark, but May Do Some Good in Diabetic Nephropathy

LAS VEGAS -- Although it missed its primary endpoint, a phosphodiesterase (PDE) inhibitor may have some effects in diabetic nephropathy, researchers reported here.

In a multicenter, randomized controlled phase II trial, there was no significant change in urine albumin-to-creatinine ratio (UACR) for patients taking CTP-499 compared with those on placebo at 24 weeks, according to Bhupinder Singh, MD, of Southwest Clinical Research Institute in Tempe, Ariz., and ...

Read more

To category page

Loading...